Tolvaptan (Jinarc®)

Jinarc® (Tolvaptan)

Tolvaptan (Jinarc®) was added to the High Tech Arrangement on 1 July 2019. A Managed Access Protocol (MAP) is in place for tolvaptan (Jinarc®). This MAP was updated in November 2022 and outlines the criteria that must be satisfied for a patient to be recommended for reimbursement of tolvaptan under the High Tech Arrangement.

The prescribing of tolvaptan under the High Tech Arrangement is confined to consultant nephrologists who have agreed to the terms of the HSE-Managed Access Protocol and have been approved by the HSE-Medicines Management Programme. ​The clinician must submit an application for individual reimbursement approval for each patient. Applications for individual reimbursement approval will only be considered from approved clinicians.

A copy of the HSE-Managed Access Protocol for tolvaptan (Jinarc®) and the application form for individual reimbursement approval can be found in the Related Files section below. 

For further information, please contact

At the end of June 2023, the HSE had approved 12 prescribers for tolvaptan under this protocol. Twenty-seven patients have accessed tolvaptan under this protocol. Click here for more information.